High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples